Olema Pharmaceuticals (OLMA) Common Equity (2020 - 2026)

Olema Pharmaceuticals (OLMA) has 7 years of Common Equity data on file, last reported at $480.5 million in Q1 2026.

• Common Equity for Q1 2026 came in at $480.5 million, up 25.3% year-over-year; the trailing twelve-month figure through Mar 2026 was $480.5 million (up 25.3% YoY), and the FY2025 annual result was $478.6 million, up 17.02% from the prior year.
• Common Equity was little changed at $480.5 million in Q1 2026 per OLMA's latest filing, from $478.6 million in the prior quarter.
• Over five years, Common Equity peaked at $480.5 million in Q1 2026 and troughed at $161.6 million in Q2 2023.
• A 5-year average of $285.2 million and a median of $253.9 million in 2023 frame the typical range for Common Equity.
• The sharpest annual moves came in 2023 and 2025: Common Equity slumped 33.99% in 2023, then soared 62.26% in 2025.
• A 5-year view of Common Equity shows it stood at $197.5 million in 2022, then grew by 28.52% to $253.9 million in 2023, then jumped by 61.08% to $409.0 million in 2024, then advanced by 17.02% to $478.6 million in 2025, then gained by 0.4% to $480.5 million in 2026.
• Business Quant data shows OLMA's Common Equity at $480.5 million in Q1 2026, $478.6 million in Q4 2025, and $307.5 million in Q3 2025.